NVTIA™ Tart Cherry-Celery Seed-Bromelain Core-Shell Composite for Uric Acid Management: Formulation Characterization and Translational Clinical Evidence

Abstract

Background: Hyperuricemia and gout remain clinically important metabolic-inflammatory conditions. Although plant-derived materials such as tart cherry products have been evaluated in human studies, single-ingredient or physically blended products often show inconsistent serum urate effects. We characterized NVTIA™ tart cherry-celery seed-bromelain composite raw material as a carrier-free core-shell system and interpreted its translational relevance against published human evidence on tart cherry and gout-related outcomes. Methods: We prepared the composite by low-temperature polyphenol-phthalide pre-assembly, bromelain surface adsorption, microfluidization configuration locking, and lyophilization. Two formulation batches were compared with a conventional physical blend for particle size, redispersion behavior, apparent polyphenol solubility, and bromelain gastric-fluid tolerance. Published human studies of tart cherry juice, cherry intake, tart cherry concentrate, and tart cherry supplementary citrate mixture were used as clinical context for uric acid management. Results: The NVTIA™ batches restored core-shell nanoparticles of 112-128 nm after reconstitution, with PDI values of 0.16-0.18. Reconstitution was completed within 22-25 s. Apparent total-polyphenol solubility reached 1.57-1.82 mg/mL, representing an 8.3-9.6-fold increase over the physical blend (0.19 mg/mL). Bromelain activity retention after simulated gastric-fluid exposure was 87.6%-89.2%. In contrast, the physical blend produced a coarse dispersion of 1427 nm, PDI 0.78, and slower redispersion. Published human evidence indicates that tart cherry juice can reduce serum urate in selected at-risk adults, cherry intake is associated with lower recurrent gout-attack risk, and tart cherry citrate mixtures may improve inflammatory or renal markers even when serum urate advantages are not superior to comparators. Conclusion: We found that structuring tart cherry polyphenols, celery seed phthalides, and bromelain into a carrier-free core-shell powder substantially improves formulation-relevant performance compared with a conventional blend. The resulting physicochemical profile supports NVTIA™ as a clinically relevant candidate raw material for uric acid management research, particularly where improved dissolution, enzyme preservation, and multi-target metabolic-inflammatory support are desired.